期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PI3K信号通路在急性髓细胞白血病治疗及耐药性调节中作用的研究进展 被引量：3

Research on PI3K signaling pathway in the treatment of acute myeloid leukemia and the regulation of drug resistance
下载PDF
导出
摘要 PI3K-AKT-mTOR通路是人体内重要的信号通路之一,其在控制细胞生长、分化、凋亡和自噬等方面都发挥着重要作用。近年来研究发现,PI3K-AKT-mTOR信号通路与急性髓系白血病(acute myeloid leukemia,AML)的发生发展密切相关。以PI3K-AKT-mTOR通路为靶点的AML治疗也取得了很大进步。本文就PI3K-AKT-mTOR信号通路的组成、表达、调控以及该信号通路相关抑制剂在AML中的研究进展进行综述,并对今后的研究方向进行展望。 The PI3K-AKT-mTOR pathway is one of the important signaling pathways in the human body,and it plays an important role in controlling cell growth,differentiation,apoptosis,and autophagy.In recent years,studies have found that PI3K-AKT-mTOR signaling pathway is closely related to the occurrence and development of AML.Great progress has also been made in the treatment of AML targeting the PI3K-AKT-mTOR pathway.This article reviews the composition,expression and regulation of PI3K-AKT-mTOR signaling pathway and the research progress of inhibitors of this signaling pathway in AML,and prospects for future research directions.
作者 史永久 李泽 李玉中 SHI Yongjiu;LI Ze;LI Yuzhong(Department of Clinical Laboratory,Second Affiliated Hospital of Dalian Medical University,Liaoning Dalian 116000,China;Dalian Medical University,Liaoning Dalian 116000,China)
机构地区 大连医科大学附属第二医院检验科 大连医科大学
出处 《现代肿瘤医学》 CAS 北大核心 2022年第16期3052-3057,共6页 Journal of Modern Oncology
关键词 急性髓系白血病 靶向治疗 PI3K-AKT-mTOR 抑制剂 acute myeloid leukemia targeted therapy PI3K-AKT-mTOR inhibitor
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献93

  • 1Agoulnik, I.U., Hodgson, M.C., Bowden, W.A., Ittmann, M.M., 2011. INPP4B: the new kid on the PI3K block. Oncotarget 2, 321-328.
  • 2Akbani, R., Ng, EK.S., Werner, H.M.J., Shahmoradgofi, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., Ling, S., Seviour, E.G., Ram, ET., Minna, J.D., Diao, L., Tong, P., Heymach, J.V., Hill, S.M., Dondelinger, F., Stidler, N., Byers, L.A., Meric-Bernstam, F., Weinstein, J.N., Broom, B.M., Verhaak, R.G.W., Liang, H., Mukherjee, S., Lu, Y., Mills, G.B., 2014. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887.
  • 3Alessi, D.R., James, S.R., Downes, C.E, Holmes, A.B., Gaffney, ER., Reese, C.B., Cohen, E, 1997. Characterization of a 3-phosphoinositide- dependent protein kinase which phosphorylates and activates protein ki- nase B . Curr. Biol. 7, 261-269.
  • 4Andjelkovic, M., Alessi, D.R., Meier, R., Fernandez, A., Lamb, N.J., Frech, M., Cron, E, Cohen, P., Lucocq, J.M., Hemmings, B.A., 1997. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272, 31515-31524.
  • 5Auger, K.R., Serunian, L.A., Soltoff, S.E, Libby, E, Cantley, L.C., 1989. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57, 167-175.
  • 6Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya- Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., Pandolfi, RR, 2006. PML inhibits HIF-I translation and neoangiogenesis through repression of mTOR. Nature 442, 779-785.
  • 7Bhatt, J.R., Finelli, A., 2014. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat. Rev. Urol. 11,517-525.
  • 8Bozulic, L., Surucu, B., Hynx, D., Hemmings, B.A., 2008. PKBAktl acts downstream of DNA-PK in the DNA double-strand break response and oromotes survival. Mol. Cell 30. 203-213.
  • 9Brazil, D.E, Yang, Z.Z., Hemmings, B.A., 2004. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233-242.
  • 10Brugge, J., Hung, M.-C., Mills, G.B., 2007. A new mutational AKTivation in the PI3K Pathway. Cancer Cell 12, 104-107.

共引文献48

同被引文献45

引证文献3

现代肿瘤医学
2022年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部